Based on the Biofrontera Inc stock forecast from 0 analysts, the average analyst target price for Biofrontera Inc is not available over the next 12 months. Biofrontera Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Biofrontera Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Biofrontera Inc’s stock price was USD 1.01. Biofrontera Inc’s stock price has changed by +3.89% over the past week, +9.76% over the past month and -65.88% over the last year.
No recent analyst target price found for Biofrontera Inc
No recent average analyst rating found for Biofrontera Inc
Company Overview Biofrontera Inc
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Read Less
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin les...Read More
Frequently Asked Questions About Biofrontera Inc (BFRI) Stock
Stock Target Advisor's fundamental analysis for Biofrontera Inc's stock is Bearish.
Unfortunately we do not have enough data on BFRI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BFRI's stock to indicate what its average analyst target is.
BFRI stock's Price/Earning ratio is 0.86.
Our analysis grades BFRI stock's Price / Earning ratio at B. This means that BFRI stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this BFRI may be undervalued for its sector.
The last closing price of BFRI's stock was USD 1.01.
The most recent market capitalization for BFRI is USD 7.75M.
Unfortunately we do not have enough analyst data on BFRI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biofrontera Inc's stock.
As per our most recent records Biofrontera Inc has 83 Employees.
Biofrontera Inc's registered address is 120 Presidential Way, Woburn, MA, United States, 01801.
You can get more information about it from Biofrontera Inc's website at https://www.biofrontera-us.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Biofrontera Inc (BFRI) Stock
Stock Target Advisor's fundamental analysis for Biofrontera Inc's stock is Bearish.
Unfortunately we do not have enough data on BFRI's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on BFRI's stock to indicate what its average analyst target is.
BFRI stock's Price/Earning ratio is 0.86.
Our analysis grades BFRI stock's Price / Earning ratio at B. This means that BFRI stock's Price/Earning ratio is above 14% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the NSD exchange.
Based on this BFRI may be undervalued for its sector.
The last closing price of BFRI's stock was USD 1.01.
The most recent market capitalization for BFRI is USD 7.75M.
Unfortunately we do not have enough analyst data on BFRI's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Biofrontera Inc's stock.
As per our most recent records Biofrontera Inc has 83 Employees.
Biofrontera Inc's registered address is 120 Presidential Way, Woburn, MA, United States, 01801.
You can get more information about it from Biofrontera Inc's website at https://www.biofrontera-us.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BFRI !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
